Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)

Posted by Matt Breese on Oct 2, 2020

Find me on:

According to our recent payer coverage analysis for Merkel cell carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Merkel cell carcinoma treatments shows that under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Merkel Cell Carcinoma-3Q2020-finalData snapshot as of Q3 2020

Trends: In April 2020, the FDA approved the supplemental biologics license application (sBLA) for Merck & Co., Inc.’s Keytruda (pembrolizumab) to include an additional recommended dosage of 400 mg every six weeks across all adult indications. The new dosing option is in addition to the approved dosage of 200 mg every three weeks.  

To read the full Reality Check on Merkel Cell Carcinoma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing